

O I F  
FEB 26 2001  
3055 301  
PATENT & TRADEMARK OFFICE

1641  
RECEIVED  
MAR 05 2001  
TECH CENTER 160023300

AMENDMENT TRANSMITTAL LETTER			DOCKET NUMBER: <b>P-LJ 3430</b>	
SERIAL NO: <b>09/228,866</b>	FILING DATE: <b>January 12, 1999</b>	EXAMINER: <b>S. Turner</b>	GROUP ART UNIT: <b>1647</b>	
INVENTION: <b>MOLECULES THAT HOME TO A SELECTED ORGAN IN VIVO</b>				

TO COMMISSIONER FOR PATENTS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C., 20231 on February 22, 2001.

By: Andrea L. Gashler  
Andrea L. Gashler, Reg. No.: 41,029

February 22, 2001  
Date of Signature

Transmitted herewith is Response to Office Action mailed November 20, 2000, in connection with the above-identified application.

- ☒ Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.
- ☒ Petition for a One Month Extension of Time is enclosed (in duplicate).
- ☒ No additional claims fee is required.
- ☐ An additional claims fee is required and has been calculated as shown below:

CLAIMS AS AMENDED

	NUMBER AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE			FEE	
							SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	29	-	29	-	0	x	\$9	\$18	=	\$0	\$
INDEPENDENT CLAIMS	15	-	15	-	0	x	\$39	\$78	=	\$0	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			<input type="checkbox"/> YES		<input checked="" type="checkbox"/> NO		\$130	\$260	=	\$0	\$
							TOTAL ADDITIONAL FEE			\$0	\$

\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

\*\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

\*\*\* If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

- ☒ A check in the amount of **\$55.00** is enclosed, \$55.00 of which covers the small entity fee for the one-month extension of time.


Inventors: Ruoslahti and Pasqualini  
Serial No.: 09/228,866  
Filed: January 12, 1999  
Page 2 of 2

- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.
- ☒ Any additional filing fees required under 37 C.F.R. 1.16.
- ☒ Any patent application processing fees under 37 C.F.R. 1.17.
- ☒ The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

February 22, 2001  
Date

Andrea L. Gashler  
Andrea L. Gashler  
Registration No. 41,029  
CAMPBELL & FLORES LLP  
4370 La Jolla Village Drive  
7<sup>th</sup> Floor  
San Diego, California 92122  
858-535-9001  
USPTO CUSTOMER NO. 23601



PATENT

Our Docket: P-LJ 3430

*Amdt*  
*16/P*  
*Linda*  
*3/19/01*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
Ruoslahti and Pasqualini

Serial No: 09/228,866

Filed: January 12, 1999

For: MOLECULES THAT HOME TO A  
SELECTED ORGAN IN VIVO

Commissioner for Patents  
Washington, D.C. 20231

) Group Art Unit: 1647

) Examiner: S. Turner

) I hereby certify that this correspondence  
) is being deposited with the United States  
) Postal Service as first class mail in an  
) envelope addressed to: Commissioner for  
) Patents, Washington, D.C., 20231, on  
) February 22, 2001.

By *Andrea L. Gashler*  
Andrea L. Gashler, Reg. No. 41,029

February 22, 2001  
Date of Signature

**RESPONSE TO OFFICE ACTION**

Responsive to the Office Action mailed  
November 20, 2000, entry of the following amendments and  
consideration of the following remarks respectfully is requested.

**AMENDMENTS**

Please amend the following claims:

*Sub E1*  
14. (Twice Amended) An isolated [A] peptide that  
selectively homes to brain, consisting of the amino acid  
sequence:

*D'*  
X<sub>1</sub>SRLX<sub>2</sub> (SEQ ID NO: 45),

wherein X<sub>1</sub> and X<sub>2</sub> each is 1 to 10 independently  
selected amino acids

and wherein said peptide exhibits at least two-fold  
greater specific binding to brain than to kidney.